BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30851906)

  • 1. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 5. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sapir E; Tao Y; Schipper MJ; Bazzi L; Novelli PM; Devlin P; Owen D; Cuneo KC; Lawrence TS; Parikh ND; Feng M
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):122-130. PubMed ID: 29066120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
    Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
    PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.
    Bettinger D; Gkika E; Schultheiss M; Glaser N; Lange S; Maruschke L; Buettner N; Kirste S; Nestle U; Grosu AL; Thimme R; Brunner TB
    BMC Cancer; 2018 Aug; 18(1):807. PubMed ID: 30092781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
    Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
    J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
    Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
    Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
    J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
    Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
    Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
    Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
    BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.
    Choi HS; Kang KM; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):209-215. PubMed ID: 32757461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching.
    Min YW; Lee JH; Gwak GY; Paik YH; Lee JH; Rhee PL; Koh KC; Paik SW; Yoo BC; Choi MS
    J Gastroenterol Hepatol; 2014 May; 29(5):1043-8. PubMed ID: 24863186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
    Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
    Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
    Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.